Premas Biotech and Oravax to test their vaccine candidate against Omicron
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
The approval is for Cytomegalovirus, a type of Herpes virus
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Subscribe To Our Newsletter & Stay Updated